Search

This report deals with a case of leiomyoma arising i n the right retroperitoneal space in a 74 years old Japanese female. The tumor, 840 grams in weight, 15 x 18 x 13 cm in size, with irregular nodular surface and partly adhered to vena cava, was successfully removed together with a part of the wall of vena cava. The postoperative course was uneventful and the patient has been in good health up to the present time, that is for about a year after surgery without any evidence of recurrence. The domestic literatures hav e been reviewed and 15 cases of smooth muscle tumors of the retroperitoneal space were collected and tabulated (Table 2). Twelve of them were malignant (leiomyosarcoma) while the remaining three were of a benign nature.

Bayrena (2-(p-aminobenzenesulfonamido)-5-methoxypyrimidi ne), a new long acting sulfonamide, was used in twenty-one patients with various urinary tract infections. Fourteen of the cases were with acute cystitis and the remaining 7 cases were with chronic urinary tract infections of various etiology. The daily dosage was i nitiated with 1 gram (2 tablets) and followed by maintenance dosage of 0.5 graiaa (1 tablet). The length of administration varied from 5 to 28 days ; about 9 days in average. Bayrena was found to be effective in 11 out of 14 cases of the acute cystitis (79 %), but only in 2 out of 7 cases of the chronic urinary tract infection (29 %). The remaining 8 cases showed no response to the Bayrena treatment. Side-effect due to the routine oral adm i n istration of Bayrena was almost negligible. A mild epigastric discomfort and anorexia were noted in only one case. As a conclusion, we believe that Bayrena is an effective chem etherapeutic agent for combating acute urinary tract infections.

Urobiotic is a combination of antibiotic (oxytetrac y cline HC1) , chemotherapeutic (sulfamethizole) and analgesic (phenazopyridine HC1) agents designed specifically for urinary tract infections. Tw e nty patients with various urinary tract infections were treated with "Urobiotic" in this study. The dosages were 1 capsule 4 times daily in 8 cases and 2 capsules 4 times daily in the remaining 12 cases, both of which continued for 5 to 7 days. The effects thus attained are summarized as follows : In patients with acute cystitis, "Urobiotic" was noted to be effective in 4 out of 5 cases in which 4 capsules daily were given, and in all of 6 cases in which the dosage was 8 capsules daily. In chronic urinary infections, consisting of 6 cases of chronic cystitis and 3 cases of chronic pyelonephritis, "Urobiotic" was noted to be not effective in all of 3 cases in which the dosage was 4 capsules daily, but effective in 4 out of 6 cases in which 8 capsules daily were given. As side effects, mild gastric discomfort was noted in only 1 patient who was given 8 capsules daily. In con c lusion, "Urobiotic" was believed to be an effective remedy not only for acute cystitis, but also for chronic urinary tract infections. Dosage recommended is 8 capsules daily.

This report deals with a case of rhabdomyosarcoma arising in the retro v esical space of a 11 months old female infant. The tumor, 4.2 x4.0 x2.7 cm in size, 40 grams in weight, with marked adhesions to the surrounding tissue was removed surgically togather with regional lymphnodes. Histological diagnosis was rhabdomyosarcoma and metastases were seen in regional lymphnodes. The postoperative course so far has been uneventful and the patient was discharged on 40 th postoperative day, after irradiation therapy with 60Co. The domestic literatures have been reviewed and 11 cases of retro p eritoneal rhabdomyosarcoma have been tabulated (table 2).

A case of non-specific granuloma of the male urethra noted in a 63-year-old Japanese male has been reported. The patient came with a complaint of a firm tumor-like mass in the perineal region accompanied by disturbances on urination. His past history was noncontributory except for an episode of acute urethritis following sexual experience about twenty years ago. By palpation, there was, in the perineal region, a firm, nodular, hen-egg sized tumor-like mass of which clinical findings suspected to be a malignant tumor. Further, urethrocystogram revealed a large shadow defect in the inferior portion of the perineal urethra. Postoperatively, however, by histopathological examination, the mass was found to be an inflammatory granuloma of a nonspecific etiology. The mass resected was 21 grams in weight, 5.5 x2.8 x 2.0 in size, firm in consistency, and markedly adhered to the surrounding tissues. In Japanes e literatures only three similar cases have been reported.

This report deals with a case of giant calculus arising in the urinary bladder of a 59 years old Japanese male, who had had a history of urinary frequency and discomfort for the previous 7 years. The calculus weighed 900 grams and the main component of which was uric acid calculus. The calculus divided into two parts with a smooth flat surface and each of them had its own nucleus. The domestic literature s have been reviewed and 39 cases of giant vesical calculus, weighing more than 200 grams, have been tabulated in weight order. The largest vesical calculus reported in Japan has been of 910 grams in weight, and this case is placed next to it.

The urinary excretion of Furadantin following the oral a d ministration of enteric coated tablet 100 mg was determined by bacteriological assay and the result was conpaired with those of the uncoated tablets 100 mg, 150 mg and 200 mg. The excretion of Furadantin enteric coated tablet into the urine was apparently slower than those of the uncoated tablets but reached to sufficiently high level in one hour and kept the effective level for eight hours. Twenty-five patients with various urinary tract infections were treated with Furad a ntin enteric coated tablet 100 mg q.i.d. for seven days in average. Bacteriological and clinical cure were obtained in 3 patients, improvement in 12 patients and no improvement in 10 patients. Mild gastric discomfort and anorexia were observed in 3 of 25 patients during the treatment with Furadantin enteric coated tablet. But the reactions were apparently milder than those of the uncoated tablet and none of our patients war forced to discontinue the treatment.

1) Furadantin was used in 47 patients with various urinar y tract infections. The dosage was 100 mg four times a day for seven days in average. Bacteriological and clinical cure were obtained in 12 patients, improvement in 19 patients but no change was observed in 16 patients. 2) Furadantin was highly effective to the patients with Escherichia or Staphylococcus infection but was not effective to those with Pseudomonas or Candida infection. 3) Unpleasant side-effects developed in 9 of 47 patients. The r e actions were mostly mild and gastrointestinal but severe headache, tinnitus, nausea and vomiting developed in an exceptional patient and, was forced to discontinue the dosage. 4) Furadantin Sensi-Disc test, was performed on 165 bacterial strains isolated from the patients with urinary tract infection and was found to be highly sensitive to Staphylococcus, Escherichia, Streptococcus viridans and Streptococcus hemolytics, relatively sensitive to Streptococcus faecalis, Corynebacterium, Klebsiella, Alkaligenes faecalis, Citrobacter etc., and resistant to Pseudomonas, Proteus, Cloaca and Candida. 5) Furadantin was found to be sensitive to 5 6% of the total 165 bacterial strains by the sensi-disc test, and when it was compared to those of the other antibiotics or chemotherapeutics, it was next to Kanamycin (73%) and was superior to Chloromycetin (49%), Erythromycin (34%), Streptomycin (30%), Terramycin (27%), Penicillin (27%), and Sulfisoxazol (6%). 6) The excretory concentration of Furadantin into the urine following the oral administration of Furadantin 100 mg was determined by bacteriological assay and it demonstrated the maximun concentration in three hours, then a rapid fall in the next hour and below the minimum inhibitory level after five hours. As a conclusion, we believe that Furadantin is an effective chemotherapeutic agent for combating urinary tract infections.